Oh wait a second. We already have a leading independent equity research that valued the company. They produced a 17 page report last month here. While not on a napkin, it's a good read and doesn't cost $100.


SeeThruEquity Initiates Coverage on Amarantus BioScience Holdings, Inc. with a Price Target of $45.34

http://finance.yahoo.com/news/seethruequity-i...00691.html